Travere Therapeutics (TVTX) Receivables - Other (2013 - 2026)

Travere Therapeutics' Receivables - Other history runs 9 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• Quarterly Receivables - Other fell 42.86% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 42.86% YoY) and the FY2025 annual result came in at $1.3 million, down 43.48% from the prior year.
• Receivables - Other was $1.2 million for Q1 2026 at Travere Therapeutics, down from $1.3 million in the prior quarter.
• Across five years, Receivables - Other topped out at $4.6 million in Q4 2023 and bottomed at $1.2 million in Q1 2026.
• A 5-year average of $2.4 million and a median of $2.2 million in 2024 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2023 — Receivables - Other soared 142.11% — and 2024, when it plunged 50.0%.
• Travere Therapeutics' Receivables - Other stood at $1.9 million in 2022, then surged by 142.11% to $4.6 million in 2023, then plunged by 50.0% to $2.3 million in 2024, then tumbled by 43.48% to $1.3 million in 2025, then declined by 7.69% to $1.2 million in 2026.
• Business Quant data shows TVTX's Receivables - Other at $1.2 million in Q1 2026, $1.3 million in Q4 2025, and $1.5 million in Q3 2025.